Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Alkermes plc ALKS

Healthcare Biotechnology
Alkermes plc is Ireland-based biopharmaceutical company that seeks to develop medicines in the field of neuroscience. The Company has a portfolio of commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical candidates in development for neurological disorders. It focuses on commercial products,... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:ALKS)

Alkermes to Participate in Upcoming Investor Conferences

PR Newswire February 26, 2025

Alkermes plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2024 and Provides Financial Expectations for 2025

PR Newswire February 12, 2025

Alkermes to Report Fourth Quarter and Year-End Financial Results on Feb. 12, 2025

PR Newswire February 5, 2025

Alkermes to Present at the 43rd Annual J.P. Morgan Healthcare Conference

PR Newswire January 2, 2025

Alkermes to Participate in Upcoming Investor Conferences

PR Newswire November 25, 2024

Alkermes to Participate in Two Upcoming Investor Conferences

PR Newswire November 11, 2024

Alkermes Highlights Presentations From Across Neuroscience Portfolio at Key Fall 2024 Scientific Conferences

PR Newswire November 7, 2024

Alkermes plc Reports Third Quarter 2024 Financial Results

PR Newswire October 24, 2024

Alkermes to Report Third Quarter Financial Results on October 24, 2024

PR Newswire October 17, 2024
View More News ››

Opinion & Analysis (NDAQ:ALKS)

VistaGen's fast-acting antidepressant targets multibillion-dollar market

The Life Sciences Report April 27, 2017

3 Biotech ETFs Rally On Merger News

Benzinga.com  December 8, 2014
View More Opinion ››

Bullboard Posts (NDAQ:ALKS)

Alkermes PLC (NASDAQ: ALKS) Records 52-Week High Wednesday M

News; $ALKS Alkermes PLC (NASDAQ: ALKS) Records 52-Week High Wednesday Morning2025-02-12 09:35:04 ET Shares of Alkermes PLC (NASDAQ...
whytestocks - February 12, 2025

Alkermes (ALKS): A Diversified Biopharma Poised for Continue

http://beyondspx.com/2024/07/31/alkermes-alks-a-diversified-biopharma-poised-for-continued-growth/
MikeTester - August 2, 2024

Alkermes plc Reports Second Quarter 2024 Financial Results

JUST IN: $ALKS Alkermes plc Reports Second Quarter 2024 Financial ResultsAlkermes plc Reports Second Quarter 2024 Financial Results PR...
whytestocks - July 24, 2024

EMERGING PARADIGMS IN TREATMENT OF MELANOMA!

$ALKS $NKTR $MGNX $CTMX $IDYA  Melanoma, a form of skin cancer, accounts for about 1% of skin cancers but is responsible for...
AviseAnalytics - January 26, 2022

Eli's exit

(Source: Bloomberg, May 23)Alkermes suffered a blow after Eli Lilly $ Co. made it clear that they were no longer going to part take in...
investology - May 25, 2008

A BIG BOOYAH BOYS

BUY AGX.V
Cheerss - January 5, 2006
View more Bullboard ››

Electrum Discovery Corp.

Electrum Discovery Corp.

Electrum Discovery Corp., formerly Medgold Resources Corp., is a Canada-based mineral exploration and development company ...
View More »